Jonathan D. Cuda

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

Tricia R. Cottrell, Elizabeth D. Thompson, Patrick M. Forde et al. · Annals of Oncology · 2018 · 557 citations · Full text

Melanoma subtypes demonstrate distinct PD-L1 expression profiles

Genevieve J. Kaunitz, Tricia R. Cottrell, Mohammed Lilo et al. · Laboratory Investigation · 2017 · 199 citations · Full text

Melanoma, Pathology, Cancer Genomics +3

Fusion of Aortic Valve Commissures in Patients Supported by a Continuous Axial Flow Left Ventricular Assist Device

James O. Mudd, Jonathan D. Cuda, Marc K. Halushka et al. · The Journal of Heart and Lung Transplantation · 2008 · 192 citations

Aortic Valve Commissures, Heart Failure, Device Therapy +10

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

Nicolás A. Giraldo, Peter Nguyen, Elizabeth L. Engle et al. · Journal for ImmunoTherapy of Cancer · 2018 · 179 citations · Full text

Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses

Jeonghyun Shin, Jeremy Vincent, Jonathan D. Cuda et al. · Journal of the American Academy of Dermatology · 2012 · 68 citations

Tumoral Pathology, Primary Melanocytic Neoplasms, Fibrohistiocytic Proliferations +9